Marrow Infiltrating Lymphocytes (MILS) as a Source of T-Cells for Chimeric Antigen Receptor (CAR) Thereapy
US-2018200367-A1 · Jul 19, 2018 · US
Marrow infiltrating lymphocytes (MILs) as a source of T-cells for chimeric antigen receptor (CAR) therapy
US11478548B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11478548-B2 |
| Application number | US-201615742684-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jul 8, 2016 |
| Priority date | Jul 8, 2015 |
| Publication date | Oct 25, 2022 |
| Grant date | Oct 25, 2022 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
In some embodiments, marrow-infiltrating lymphocytes (“MILs”) comprising a chimeric antigen receptor (“CAR”) are provided. In some aspects, the embodiments relate to a method for making a recombinant MIL, comprising obtaining bone marrow comprising MILs; and transfecting, transforming, or transducing the MILs with a nucleic acid encoding a chimeric antigen receptor. In some aspects, the embodiments relate to a method for treating a condition in a subject, comprising administering to the subject a MIL comprising a CAR.
First claim
Opening claim text (preview).
What is claimed is: 1. A marrow infiltrating lymphocyte (“MIL”), comprising a chimeric antigen receptor (“CAR”), wherein: the CAR comprises a scFV antigen-binding domain that can bind to an extracellular domain of CD19 or CD38; and a transmembrane domain of CD19 or CD8, and an intracellular domain selected from the group consisting of 4-1BB, CD3ζ, and a combination thereof and wherein the MIL is autologous MIL isolated from a cancer patient. 2. The MIL of claim 1 , wherein the MIL is CD3+, CD4+, CD8+, or a combination thereof. 3. The MIL of claim 1 , wherein the MIL is CD45RO+, CD62L+, or CXCR4+. 4. The MIL of claim 1 , wherein the MIL is 4-1BB+. 5. The MIL of claim 1 , wherein the MIL is interferon γ+ and/or is CD138+. 6. The MIL of claim 1 , wherein the MIL is CD33+. 7. The MIL of claim 1 , wherein the MIL is CD34-. 8. A method of inhibiting the growth of a neoplastic cell that expresses CD19 or CD38 in a subject, comprising administering to the subject the CD19 or CD38 binding MIL of claim 1 .
Assignees
Inventors
Classifications
Genetically modified cells · CPC title
CD28, CD152 · CPC title
Antimycotics · CPC title
Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE · CPC title
Antivirals · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11478548B2 cover?
- In some embodiments, marrow-infiltrating lymphocytes (“MILs”) comprising a chimeric antigen receptor (“CAR”) are provided. In some aspects, the embodiments relate to a method for making a recombinant MIL, comprising obtaining bone marrow comprising MILs; and transfecting, transforming, or transducing the MILs with a nucleic acid encoding a chimeric antigen receptor. In some aspects, the embodim…
- Who is the assignee on this patent?
- Univ Johns Hopkins
- What technology area does this patent fall under?
- Primary CPC classification A61K39/39558. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Oct 25 2022 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 3 related publications on this page (citations in our corpus or others sharing the same primary CPC).